Mucin 5AC

Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Insights H1, 2020

Retrieved on: 
Monday, March 16, 2020
Pulmonology, Medicine, Health, Chronic lower respiratory diseases, COPD: Journal of Chronic Obstructive Pulmonary Disease, Chronic obstructive pulmonary disease, Respiratory therapy, Pulmonary disease, chronic obstructive, severe early-onset, Mucin 5AC

DUBLIN, March 16, 2020 /PRNewswire/ -- The "Chronic Obstructive Pulmonary Disease (COPD) Global Clinical Trials Review H1, 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 16, 2020 /PRNewswire/ -- The "Chronic Obstructive Pulmonary Disease (COPD) Global Clinical Trials Review H1, 2020" report has been added to ResearchAndMarkets.com's offering.
  • Chronic Obstructive Pulmonary Disease (COPD) Global Clinical Trials Review H1, 2020 provides an overview of Chronic Obstructive Pulmonary Disease (COPD) Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Chronic Obstructive Pulmonary Disease (COPD).
  • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.

Global Chronic Obstructive Pulmonary Disease Clinical Trials Review - H1, 2020 - ResearchAndMarkets.com

Retrieved on: 
Friday, March 13, 2020
Health, Clinical trials, Pulmonology, Medicine, Health, Chronic lower respiratory diseases, COPD: Journal of Chronic Obstructive Pulmonary Disease, Chronic obstructive pulmonary disease, Pulmonary disease, chronic obstructive, severe early-onset, Mucin 5AC

The "Chronic Obstructive Pulmonary Disease (COPD) Global Clinical Trials Review, H1, 2020" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Chronic Obstructive Pulmonary Disease (COPD) Global Clinical Trials Review, H1, 2020" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This clinical trial report, Chronic Obstructive Pulmonary Disease (COPD) Global Clinical Trials Review, H1, 2020" provides an overview of Chronic Obstructive Pulmonary Disease (COPD) Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Chronic Obstructive Pulmonary Disease (COPD).
  • Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe.

KALY – Kali-Extracts Files Patent Application For CBD Formulation To Treat COPD Derived From Existing Kali-Extracts Patented Cannabis Extraction Process

Retrieved on: 
Wednesday, August 21, 2019
Pulmonology, Chronic lower respiratory diseases, Respiratory diseases, Respiratory system, Organ systems, Chronic obstructive pulmonary disease, Respiratory disease, COPD: Journal of Chronic Obstructive Pulmonary Disease, Obstructive lung disease, Mucin 5AC

The formulation for the treatment of symptoms associated with COPD and other similar respiratory conditions has been derived from the companys existing patented cannabis extraction process.

Key Points: 
  • The formulation for the treatment of symptoms associated with COPD and other similar respiratory conditions has been derived from the companys existing patented cannabis extraction process.
  • The company has also filed to register a trademark on the name RespRx as the brand name for its CBD formulation to treat the symptoms associated with COPD and other similar respiratory conditions.
  • KALY plans to publish a website on Friday, August 23rd, dedicated to its new CBD formulation, RespRx, for treating symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions.
  • The RespRx website to be published Friday will include details on KALYs recent patent and trademark applications for the RespRx CBD formulation.

Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market - Global Industry Analysis, Trends, Market Size, and Forecasts to 2025 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 16, 2019
Health, Pharmaceutical, Chronic lower respiratory diseases, Medical terminology, Medicine, Chronic condition, Chronic obstructive pulmonary disease, Health, Articles, Pulmonary disease, chronic obstructive, severe early-onset, Mucin 5AC

The "Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2025" report has been added to ResearchAndMarkets.com's offering.
  • The report on the global chronic obstructive pulmonary disease therapeutics market provides qualitative and quantitative analysis for the period from 2017 to 2025.
  • The study on chronic obstructive pulmonary disease therapeutics market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2017 to 2025.
  • The report on chronic obstructive pulmonary disease therapeutics market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global chronic obstructive pulmonary disease therapeutics market over the period of 2017 to 2025.

Global Chronic Obstructive Pulmonary Disease Market and Competitive Landscape Report 2018

Retrieved on: 
Tuesday, October 9, 2018
Medical terminology, Medicine, Chronic condition, Respiratory disease, Hypertension, Bronchodilators, Muscarinic antagonists, Mucin 5AC, Draft:Genetic epidemiology of Alpha-1 antitrypsin deficiency

The "Global Chronic Obstructive Pulmonary Disease Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Chronic Obstructive Pulmonary Disease Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering.
  • Global Chronic Obstructive Pulmonary Disease Market and Competitive Landscape - 2018, provides comprehensive insights into Chronic Obstructive Pulmonary Disease pipeline, epidemiology, market valuations, product sales, market forecast, product forecasts, and market shares.
  • The research is classified into following sections - Chronic Obstructive Pulmonary Disease overview with definitions, symptoms, etiology, diagnosis, treatment options; Chronic Obstructive Pulmonary Disease pipeline insights covering late stage clinical trials pipeline; Chronic Obstructive Pulmonary Disease prevalence trends by countries; Chronic Obstructive Pulmonary Disease market size and forecast by countries, market events, trends; product sales and forecast by countries; market shares by countries.
  • Chronic Obstructive Pulmonary Disease pipeline: Find out the drugs in clinical trials for Chronic Obstructive Pulmonary Disease by stages, phase 3 clinical trials, phase 2 clinical trials, and phase 1 clinical trials, by pharmacological class, by company
    Chronic Obstructive Pulmonary Disease epidemiology: Find out the prevalence of Chronic Obstructive Pulmonary Disease by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan; prevalence forecast to 2023
    Chronic Obstructive Pulmonary Disease products: Identify key products marketed and prescribed for Chronic Obstructive Pulmonary Disease by brand name, by molecule, by company, by branded / generic, by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan
    Chronic Obstructive Pulmonary Disease market size: Find out the market size for Chronic Obstructive Pulmonary Disease drugs by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan; Find out how the market advanced from 2014
    Chronic Obstructive Pulmonary Disease drug sales: Find out the sales of Chronic Obstructive Pulmonary Disease drugs by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan, Global
    Chronic Obstructive Pulmonary Disease drugs sales forecast: Sales forecast for Chronic Obstructive Pulmonary Disease drugs to 2023 by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan
    Chronic Obstructive Pulmonary Disease market share analysis: Find out the market shares of Chronic Obstructive Pulmonary Disease drugs and outlook by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan

ProterixBio Presents Results from Multiple COPD Clinical Studies at the American Thoracic Society International Conference

Retrieved on: 
Tuesday, May 22, 2018
Chronic lower respiratory diseases, Chronic obstructive pulmonary disease, Respiratory therapy, Health, Medicine, Mucin 5AC, Pulmonary rehabilitation

BILLERICA, Mass., May 22, 2018 /PRNewswire/ -- ProterixBio, Inc. today announced that results from three clinical studies of subjects with chronic obstructive pulmonary disease (COPD) were presented at the American Thoracic Society International Conference this week.

Key Points: 
  • BILLERICA, Mass., May 22, 2018 /PRNewswire/ -- ProterixBio, Inc. today announced that results from three clinical studies of subjects with chronic obstructive pulmonary disease (COPD) were presented at the American Thoracic Society International Conference this week.
  • A second presentation focused on results from an ancillary study as part of the SubPopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS).
  • "There is an unmet need for quantitative, biological measures of disease activity in COPD," said Michael F. Miller, Ph.D., president and chief executive officer of ProterixBio.
  • "These latest results build on our previous findings and further strengthen the evidence supporting advanced molecular assessments to impact clinical care and therapeutics development."